Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Hong-Yu Li

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentCollege of Pharmacy, College of Provost
DivisionPharmaceutical Science
Address200 South Cedar
Mail Slot # 622
Little Rock AR 72202
Phone501-296-1154
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA249282     (SHAH, NEIL P)Dec 15, 2020 - Nov 30, 2025
    NIH
    Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance
    Role: Co-Principal Investigator

    R01CA194094     (LI, HONG-YU)Sep 1, 2016 - Jul 31, 2019
    NIH/Nat. Cancer Institute
    Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
    Role: Principal Investigator

    340316     (LI, HONG-YU)Apr 1, 2016 - Jun 30, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Arizona
    Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
    Role: Principal Investigator

    R01CA197178     (LI, HONG-YU)Sep 30, 2015 - Aug 31, 2021
    NIH
    Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer
    Role: Principal Investigator

    R01CA197178     (LI, HONG-YU)Sep 30, 2015 - Aug 31, 2021
    NIH
    Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer
    Role: Principal Investigator

    R41CA195826     (LI, HONG YU)Sep 1, 2015 - Dec 31, 2016
    NIH
    Pre-IND Study of Pz-1, a dual pan-RET/VEGFR2 inhibitor for the Treatment of RET-driven Disease
    Role: Principal Investigator

    R01CA194094     (LI, HONG-YU)Aug 1, 2015 - Jul 31, 2020
    NIH
    Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
    Role: Principal Investigator

    P20GM109005     (BOERMA, MARJAN)Jun 24, 2015 - May 31, 2025
    NIH
    Center for Studies of Host Response to Cancer Therapy
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Lei J, Song GT, He LJ, Luo YF, Tang DY, Lin HK, Frett B, Li HY, Chen ZZ, Xu ZG. Correction: One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chem Commun (Camb). 2020 Feb 18; 56(14):2210. PMID: 32031562.
      View in: PubMed
    2. Lei J, Song GT, He LJ, Luo YF, Tang DY, Lin HK, Frett B, Li HY, Chen ZZ, Xu ZG. One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chem Commun (Camb). 2020 Feb 18; 56(14):2194-2197. PMID: 31971170.
      View in: PubMed
    3. Gunaganti N, Kharbanda A, Lakkaniga NR, Zhang L, Cooper R, Li HY, Frett B. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chem Commun (Camb). 2018 Nov 15; 54(92):12954-12957. PMID: 30375586.
      View in: PubMed
    Li's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description